Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, January 8, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Gilead Sciences, Inc. (NASDAQ:GILD), Express Scripts Holding Company (NASDAQ:ESRX), Sanofi SA (ADR) (NYSE:SNY), Agilent Technologies Inc. (NYSE:A) and Kythera Biopharmaceuticals Inc. (NASDAQ:KYTH). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Gilead Sciences, Inc. Research Report
On January 3, 2014, Gilead Sciences, Inc.'s (Gilead) stock declined 1.18%, ending the day's trading session at $74.32. Over the previous three trading sessions, shares of Gilead declined 1.01%, compared to the Nasdaq Composite Index, which declined 0.54% during the same period. The Full Research Report on Gilead Sciences, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Express Scripts Holding Company Research Report
On January 3, 2014, Express Scripts Holding Company (Express Scripts) announced that the Company is scheduled to make a presentation at the J.P. Morgan Healthcare Conference on January 15, 2014 at 8:00 a.m. PT (11:00 a.m. ET) at the Westin St. Francis in San Francisco, California. The Company added that interested parties may view a live broadcast of the presentation by visiting the investor relations section of Express Scripts' website. According to the Company, the presentation will also be archived and made available for replay for 14 days. The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Sanofi SA Research Report
On January 2, 2014, Sanofi SA (Sanofi) reported that it will expand access to information and data from clinical trials, sponsored by companies of the Sanofi group, beginning from January 2014. According to the Company, this move of Sanofi comes in support of industry-wide efforts to promote a set of Principles for Responsible Sharing of Clinical Data that the Pharmaceutical Research and Manufacturers of America (PhRMA) and the European Federation of Pharmaceutical Industries and Associations (EFPIA), jointly released in July 2013. The Company said that it will provide access to clinical trial data and related documents, including Clinical Study Reports (CSR), for studies sponsored by Sanofi companies that conduct clinical studies in humans. Sanofi stated that the studies must have been submitted to U.S. and E.U. regulatory agencies and the product must have been approved by both agencies on or after January 1, 2014, while for Sanofi Pasteur, the product must have been approved by either agency on or after January 1, 2014. The Company added that it will continue to submit for publication of the results from all company-sponsored clinical studies, regardless of outcome. Further, Sanofi said it is working with the regulators to adopt mechanisms so that clinical study sponsors will be able to provide lay language summary results directly to participating individuals. The Full Research Report on Sanofi SA (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Agilent Technologies Inc. Research Report
On January 3, 2014, Agilent Technologies Inc. (Agilent) announced that the Company's President and CEO, Bill Sullivan will make a presentation at the 32nd Annual J.P. Morgan Healthcare Conference, to be held in Westin St. Francis Hotel, San Francisco, California on January 13, 2014 at 9:00 a.m. PT. The Company added that interested parties may view a webcast of the presentation via links provided at the Company's website. The Full Research Report on Agilent Technologies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Kythera Biopharmaceuticals Inc. Research Report
On January 3, 2014, Kythera Biopharmaceuticals Inc.'s (Kythera Biopharmaceuticals) stock declined 4.29%, ending the day's trading session at $35.70. Over the previous three trading sessions, shares of Kythera Biopharmaceuticals declined 6.30%, compared to the Nasdaq Composite Index, which declined 0.54% during the same period. The Full Research Report on Kythera Biopharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner